Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

75 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunity.
Kleczko EK, Hinz TK, Nguyen TT, Gurule NJ, Navarro A, Le AT, Johnson AM, Kwak J, Polhac DI, Clambey ET, Weiser-Evans M, Merrick DT, Yang MC, Patil T, Schenk EL, Heasley LE, Nemenoff RA. Kleczko EK, et al. Among authors: clambey et. NPJ Precis Oncol. 2023 Feb 4;7(1):15. doi: 10.1038/s41698-023-00355-2. NPJ Precis Oncol. 2023. PMID: 36739466 Free PMC article.
Complement Activation via a C3a Receptor Pathway Alters CD4+ T Lymphocytes and Mediates Lung Cancer Progression.
Kwak JW, Laskowski J, Li HY, McSharry MV, Sippel TR, Bullock BL, Johnson AM, Poczobutt JM, Neuwelt AJ, Malkoski SP, Weiser-Evans MC, Lambris JD, Clambey ET, Thurman JM, Nemenoff RA. Kwak JW, et al. Among authors: clambey et. Cancer Res. 2018 Jan 1;78(1):143-156. doi: 10.1158/0008-5472.CAN-17-0240. Epub 2017 Nov 8. Cancer Res. 2018. PMID: 29118090 Free PMC article.
Targeted overexpression of prostacyclin synthase inhibits lung tumor progression by recruiting CD4+ T lymphocytes in tumors that express MHC class II.
Li HY, McSharry M, Walker D, Johnson A, Kwak J, Bullock B, Neuwelt A, Poczobutt JM, Sippel TR, Keith RL, Weiser-Evans MCM, Clambey E, Nemenoff RA. Li HY, et al. Oncoimmunology. 2018 Feb 13;7(5):e1423182. doi: 10.1080/2162402X.2017.1423182. eCollection 2018. Oncoimmunology. 2018. PMID: 29721380 Free PMC article.
Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration.
Oweida A, Hararah MK, Phan A, Binder D, Bhatia S, Lennon S, Bukkapatnam S, Van Court B, Uyanga N, Darragh L, Kim HM, Raben D, Tan AC, Heasley L, Clambey E, Nemenoff R, Karam SD. Oweida A, et al. Clin Cancer Res. 2018 Nov 1;24(21):5368-5380. doi: 10.1158/1078-0432.CCR-18-1038. Epub 2018 Jul 24. Clin Cancer Res. 2018. PMID: 30042205 Free PMC article.
CD8+ T cells modulate autosomal dominant polycystic kidney disease progression.
Kleczko EK, Marsh KH, Tyler LC, Furgeson SB, Bullock BL, Altmann CJ, Miyazaki M, Gitomer BY, Harris PC, Weiser-Evans MCM, Chonchol MB, Clambey ET, Nemenoff RA, Hopp K. Kleczko EK, et al. Among authors: clambey et. Kidney Int. 2018 Dec;94(6):1127-1140. doi: 10.1016/j.kint.2018.06.025. Epub 2018 Sep 21. Kidney Int. 2018. PMID: 30249452 Free PMC article.
Tumor-intrinsic response to IFNγ shapes the tumor microenvironment and anti-PD-1 response in NSCLC.
Bullock BL, Kimball AK, Poczobutt JM, Neuwelt AJ, Li HY, Johnson AM, Kwak JW, Kleczko EK, Kaspar RE, Wagner EK, Hopp K, Schenk EL, Weiser-Evans MC, Clambey ET, Nemenoff RA. Bullock BL, et al. Among authors: clambey et. Life Sci Alliance. 2019 May 27;2(3):e201900328. doi: 10.26508/lsa.201900328. Print 2019 Jun. Life Sci Alliance. 2019. PMID: 31133614 Free PMC article.
75 results